A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients
Open Access
- 1 October 2001
- journal article
- clinical trial
- Published by Elsevier BV in Annals Of Oncology
- Vol. 12 (10), 1375-1381
- https://doi.org/10.1023/a:1012539225493
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Feasibility and safety of Navelbine oral (NVBpo) with an intrapatient dose escalation versus Navelbine intravenous (NVBiv) in advanced/metastatic non small cell lung cancer (NSCLC)Lung Cancer, 2000
- 1118: Absolute bioavailability and pharmacokinetics (PK) of oral vinorelbine (VRL) in patients (pts) with solid tumorsEuropean Journal Of Cancer, 1997
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997
- Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II studyCancer Chemotherapy and Pharmacology, 1996
- Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer.Journal of Clinical Oncology, 1995
- Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.Journal of Clinical Oncology, 1994
- Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trialAnnals Of Oncology, 1994